Treatment for asthma with α4-specific antibodies
US7482003B2 · kind B2 · utility
6Cited by
17References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 29, 2006 |
| Grant date | Jan 27, 2009 |
| Priority date | — |
| Expiry date | Apr 11, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.